News from Nanoscope
Nanoscope Therapeutics to Move Corporate Headquarters to Dallas
“Moving to Trinity Towers places us in the heart of the growing healthcare community in Dallas,” said Nanoscope Co-Founder and CEO, Sulagna Bhattacharya. “Rapid growth is expected for Nanoscope in 2023 and Trinity Towers provides an excellent space for our expanding team to collaborate.”
READ COMPLETE PRESS RELEASE
Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.

Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
LEARN ABOUT OUR TECHNOLOGY
Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.
Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration

Nanoscope News & Events
-
Nanoscope Therapeutics to Move Corporate Headquarters to DallasAugust 16, 2022
-
Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt DiseaseJuly 25, 2022
-
Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation SummitJuly 14, 2022
-
Nanoscope's Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual MeetingJuly 12, 2022
-
Nanoscope's Top Executive Team to Participate and Present at World Orphan Drug Congress USA MeetingJuly 11, 2022
-
Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial OfficerJuly 5, 2022
-
Nanoscope Therapeutics CEO Sulagna Bhattacharya Named Winner of EY Entrepreneur Of The Year® 2022 Central Plains AwardJune 27, 2022
-
Nanoscope Therapeutics to Provide Update on Optogenetic Approaches for Vision Restoration at BIO InternationalJune 13, 2022